

#2918
DIA
1/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DYMECKI

Appln. No. 08/866,279

Filing Date: May 30, 1997



Group Art Unit: 1632

Examiner: A.-M. Baker

FOR: USE OF FLP RECOMBINASE IN MICE

AMENDMENT & REPLY TO OFFICE ACTION

RECEIVED
JAN 23 2002
TECH CENTER 1600/2900

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

This Reply is responsive to the Office Action dated July 18, 2001. Please enter the following Amendments and Remarks and the Declaration under 37 CFR 1.132 attached hereto, prior to further examination of the subject application.

IN THE CLAIMS

Please add the following new claims prior to further examination:

--50. (New) The transgenic mouse according to claim 12, wherein transcription of said another transgene is controlled by a regulatory region selected from the group consisting of regulatory regions from the genes β -actin, phosphoglycerate kinase, HMG-CoA reductase, major histocompatibility complex class I, β 2-microglobulin, HSV thymidine kinase, Rous Sarcoma Virus regulatory elements, CMV immediate early gene, and SV40 origin.

Considered 2/6/02.
Do not enter: AMB

Sub 1
X